Clinical trials: Pharmacogenetics
Substance Use Disorder
OPAL: "Opiates and PhArmacoLogy"
The aim of this study is to determine the current prevalence of co-addictions, including problem/pathological gambling, in patients receiving Opiate Substitution Treatment (OST), and to then compare patients receiving OST with or…
- Trial name
- OPAL (NCT01847729)
- Where
- 7 sites in France
- Volunteers
- 263 people
- Sponsor
- Nantes University Hospital
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer
In this trial, FLOT will be evaluated as therapy option for elderly patients (>65 years) with advanced gastric cancer in comparison to the well established FLO scheme.
- Trial name
- NCT00737373
- Testing
- Docetaxel, 5-Fluorouracil, Oxaliplatin
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- Krankenhaus Nordwest
CDK4/6 Inhibitor, Breast Cancer
Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors
The goal of this research study is to reduce adverse effects of anti-cancer medications known as kinase inhibitors, while preserving their therapeutic benefits. There have been major advances in the way cancers are treated.
- Conditions
- CDK4/6 Inhibitor, Breast Cancer, CYP3A4 Protein, Human, Drug Interaction
- Trial name
- NCT07100054
- Testing
- Whole gene sequencing, Drug-drug interaction analysis, Biomarker analysis
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Colorectal Cancer
Verification of a Pharmacogenetic Approach to Customizing Chemotherapy to Asians
Interethnic variability in chemotherapy response is becoming increasingly evident, making approaches for customizing chemotherapy treatment to different ethnic populations desirable.
- Trial name
- NCT01596361
- Where
- Singapore
- Volunteers
- 750 people
- Sponsor
- National University Hospital, Singapore
Hepatocellular Carcinoma
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
This study aims to determine the predictive effect of ATG10 and IL6 genetic polymorphisms in safety and efficacy of sorafenib used for the treatment of Egyptian HCC patients.
- Trial name
- NCT06030895
- Testing
- Sorafenib Tablets
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Damanhour University
Asthma
Pharmacogenetics of b2-Agonists in Asthma.
This study will help to find out if having a certain genetic makeup influences how a person with asthma responds to salmeterol, one of the two drugs in Advair(R).
- Trial name
- NCT00708227
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Nemours Children's Clinic
Breast Cancer
An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment
For many years scientists and cancer researchers have been trying to find out why some people benefit more from anti-cancer medications than other people who receive the same amount and same kind of medications.
- Trial name
- NCT00131612
- Testing
- FEC 100
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- AHS Cancer Control Alberta
Hemosiderosis
Pharmacogenetic Study in Patients Received Iron Chelating Agent
To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.
- Trial name
- NCT01623895
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Rejection Heart Transplant, Immunosuppression
Improving Immunosuppressive Therapy in Heart Transplantation
Cardiac allograft rejection (CAR) occurs in 30% to 40% of transplant recipients within the first year post-transplant, and carries an increased risk of both acute graft failure and reduced graft longevity.
- Trial name
- NCT03932539
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
DPYD Gene Mutation, Gastrointestinal Cancer
Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines
5-fluorouracil and capecitabine, sometimes called 5-FU, fluoropyrimidines, or Xeloda are a type of chemotherapy. Many people have side effects from these drugs like nausea, diarrhea, or blood problems.
- Conditions
- DPYD Gene Mutation, Gastrointestinal Cancer, Health Care Seeking Behavior
- Trial name
- DPYD Nudges (NCT06559462)
- Testing
- Focus Group, Discrete Choice
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer
Pharmacogenetic DNA Bank
Aims of Research Proposal: 1. To build a DNA bank in association with a comprehensive database of treatment outcomes and toxicities of cancer patients. 2.
- Trial name
- NCT00941200
- Testing
- Blood collection
- Where
- Singapore
- Volunteers
- 5,000 people
- Sponsor
- National University Hospital, Singapore
Female Infertility
Hormone Evaluation in Artificial Reproductive Technology
The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation.
- Trial name
- HEART (NCT03737253)
- Testing
- Follitropin alpha, Menotropin
- Where
- 2 sites in Poland, Sweden
- Volunteers
- 810 people
- Sponsor
- Lund University
Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions
Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction
The research is planned as a prospective nested case-control study. The plan is to recruit about 1,200 consecutive subjects whose pharmacotherapy involves the drug(s) of interest within 4.5 years.
- Conditions
- Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Drugs
- Trial name
- NCT05307718
- Testing
- Oral Anticoagulant, Direct-Acting
- Where
- Croatia
- Volunteers
- 1,200 people
- Sponsor
- Clinical Hospital Centre Zagreb
Attention Deficit Hyperactivity Disorder
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
The ultimate goal of this study is to find the association between specific polymorphism of candidate genes and medication response in attention deficit hyperactivity disorder (ADHD) patients.
- Trial name
- NCT00916786
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Major Depressive Disorder
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants
The objective of this pilot study is to determine the genetic polymorphism rate of CYP450 2D6 and 2C19 metabolic enzymes in patients with significant adverse effects from antidepressants, compared to a population of patients who…
- Trial name
- NCT00360256
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Augusta University
Rheumatoid Arthritis
Regional Registry-based Biobank Development and Pharmacogenetic Analysis in Rheumatoid Arthritis
Aim of this project is the building-up of an integrated model of multidisciplinary research tools to support large-scale and high-quality disease-based studies.
- Trial name
- RABiobank (NCT03555240)
- Testing
- Biobank creation and Pharmacogenetic analysis
- Where
- 10 sites in Italy
- Volunteers
- 600 people
- Sponsor
- Istituto Ortopedico Rizzoli
Thromboembolism
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention.
- Trial name
- GIFT (NCT01006733)
- Testing
- Pharmacogenetic, Target INR 1.8
- Where
- 6 sites in United States
- Volunteers
- 1,598 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Cardiovascular Diseases, Dyslipidemias
Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins
This is a Phase IV multicentre adaptive single-blinded randomized clinical trial if preemptively genotyping populations at risk of cardiovascular disease susceptible of receiving high or moderate doses of statin therapy is…
- Conditions
- Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction, Pharmacogenic Myopathy
- Trial name
- PREVESTATGx (NCT06262685)
- Testing
- Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines, Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines, Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines
- Where
- Spain
- Volunteers
- 216 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Patients With Acute Myeloid Leukemia, Patients Receiving Induction/Consolidation Chemotherapy
Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia
The main component in the treatment of acute myeloid leukemia (AML) is consist of anthracycline (such as daunorubicin or idarubicin) and cytarabine.
- Trial name
- NCT01106144
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center
Advanced Solid Tumors
A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours
OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore.
- Trial name
- NCT01867073
- Testing
- Biomarker
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore